Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jens Meiler

Showing results (401-410 of 432) with videos related to

Pageof 44
Sort By:
Journal of Medicinal Chemistry|September 21, 2013
Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254)Mark Turlington, Meredith J Noetzel, Aspen Chun, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 3, 2016
Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion proteinJarrod J Mousa, Marion F Sauer, Alexander M Sevy, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 14, 2019
Structural, functional, and behavioral insights of dopamine dysfunction revealed by a deletion in <i>SLC6A3</i>Nicholas G Campbell, Aparna Shekar, Jenny I Aguilar, et al.
JCI Insight|January 8, 2026
High throughput screening identifies a trafficking corrector for long-QT syndrome associated KCNQ1 variantsKatherine R Clowes Moster, Carlos G Vanoye, Ana C Chang-Gonzalez, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
High Throughput Screening Identifies a Small Molecule Trafficking Corrector for Long-QT Syndrome Associated KCNQ1 VariantsKatherine R Clowes Moster, Carlos G Vanoye, Ana C Chang-Gonzalez, et al.
Molecular Genetics & Genomic Medicine|April 18, 2019
IgG4-related disease: Association with a rare gene variant expressed in cytotoxic T cellsJohn H Newman, Aaron Shaver, Jonathan H Sheehan, et al.
Nature|April 20, 2018
Structural basis of ligand binding modes at the neuropeptide Y Y<sub>1</sub> receptorZhenlin Yang, Shuo Han, Max Keller, et al.
American Journal of Human Genetics|August 8, 2025
Genomics-informed drug-repurposing strategy identifies two therapeutic targets for preventing liver disease associated with metabolic dysfunctionHannah M Seagle, Alexis T Akerele, Joseph A DeCorte, et al.
Nature Communications|April 14, 2025
Drugit: crowd-sourcing molecular design of non-peptidic VHL bindersThomas Scott, Christian Alan Paul Smethurst, Yvonne Westermaier, et al.
Medrxiv : the Preprint Server for Health Sciences|March 4, 2025
Genomics-Informed Drug Repurposing Strategy Identifies Novel Therapeutic Targets for Metabolic Dysfunction-Associated Steatotic Liver DiseaseHannah M Seagle, Alexis T Akerele, Joseph A DeCorte, et al.
Pageof 44

Showing results (401-410 of 432) with videos related to

Sort By:
Pageof 44
Journal of Medicinal Chemistry|September 21, 2013
Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254)Mark Turlington, Meredith J Noetzel, Aspen Chun, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 3, 2016
Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion proteinJarrod J Mousa, Marion F Sauer, Alexander M Sevy, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 14, 2019
Structural, functional, and behavioral insights of dopamine dysfunction revealed by a deletion in <i>SLC6A3</i>Nicholas G Campbell, Aparna Shekar, Jenny I Aguilar, et al.
JCI Insight|January 8, 2026
High throughput screening identifies a trafficking corrector for long-QT syndrome associated KCNQ1 variantsKatherine R Clowes Moster, Carlos G Vanoye, Ana C Chang-Gonzalez, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
High Throughput Screening Identifies a Small Molecule Trafficking Corrector for Long-QT Syndrome Associated KCNQ1 VariantsKatherine R Clowes Moster, Carlos G Vanoye, Ana C Chang-Gonzalez, et al.
Molecular Genetics & Genomic Medicine|April 18, 2019
IgG4-related disease: Association with a rare gene variant expressed in cytotoxic T cellsJohn H Newman, Aaron Shaver, Jonathan H Sheehan, et al.
Nature|April 20, 2018
Structural basis of ligand binding modes at the neuropeptide Y Y<sub>1</sub> receptorZhenlin Yang, Shuo Han, Max Keller, et al.
American Journal of Human Genetics|August 8, 2025
Genomics-informed drug-repurposing strategy identifies two therapeutic targets for preventing liver disease associated with metabolic dysfunctionHannah M Seagle, Alexis T Akerele, Joseph A DeCorte, et al.
Nature Communications|April 14, 2025
Drugit: crowd-sourcing molecular design of non-peptidic VHL bindersThomas Scott, Christian Alan Paul Smethurst, Yvonne Westermaier, et al.
Medrxiv : the Preprint Server for Health Sciences|March 4, 2025
Genomics-Informed Drug Repurposing Strategy Identifies Novel Therapeutic Targets for Metabolic Dysfunction-Associated Steatotic Liver DiseaseHannah M Seagle, Alexis T Akerele, Joseph A DeCorte, et al.
Pageof 44